# Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan

> **NCT04559581** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 425 (actual)

## Conditions studied

- Lung Diseases, Interstitial

## Interventions

- **DRUG:** Nintedanib

## Key facts

- **NCT ID:** NCT04559581
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-02
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-01-22
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04559581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04559581, "Post-marketing Surveillance of Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype in Japan". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04559581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*